多发性骨髓瘤患者血清中LncRNA PRAL的表达及与临床病理参数和预后的关系  

Expression of LncRNA PRAL in serum of patients with multiple myeloma and its relationship with clinicopathological parameters and prognosis

作　　者：张李玉 顾喆贇 周晓丹 王铃 陶健[1] ZHANG Liyu;GU Zheyun;ZHOU Xiaodan;WANG Ling;TAO Jian(Department of Hematology,the Second Affiliated Hospital of Nantong University,Jiangsu Province,Nantong226001,China)

机构地区：[1]南通大学第二附属医院血液科,江苏南通226001

出　　处：《中国医药导报》2020年第34期39-42,47,共5页China Medical Herald

基　　金：江苏省自然科学基金资助项目(2017MS0227)。

摘　　要：目的研究多发性骨髓瘤(MM)患者血清长链非编码RNA(LncRNA)PRAL的表达及与临床病理参数和预后的关系。方法选取2016年1月—2017年1月南通大学第二附属医院(以下简称“我院”)诊治的82例MM患者的临床资料为病例组,以我院同期诊治的患其他血液疾病患者50例作为病例对照组,51名我院同期健康查体的人群作为健康对照组。应用荧光实时定量PCR检测各组血清中LncRNA PRAL的表达,统计学分析各组间表达差异及与MM临床病理特征间的关系。以血清LncRNA PRAL表达水平的均值2.125为界,将82例MM患者分为高LncRNA PRAL表达组40例和低LncRNA PRAL表达组42例,比较两组的治疗效果。Kaplan-Meier生存分析(Log-rank检验)不同LncRNA PRAL表达水平患者的预后差异。结果病例组LncRNA PRAL的表达明显低于病例对照组及健康对照组(P<0.05)。高国际分期系统(ISS)分期的MM患者血清中LncRNA PRAL表达水平明显低于低ISS分期的MM患者(P<0.05),而不同年龄、性别、诊断分型、Durie-Salmon分期、血乳酸脱氢酶、血钙及血红蛋白水平患者血清中LncRNA PRAL的相对表达量差异无统计学意义(均P>0.05)。病例组LncRNA PRAL高表达组患者的疗效优于LncRNA PRAL低表达组(P<0.05)。低LncRNA PRAL表达组3年总体生存率明显低于高LncRNA PRAL表达组,平均生存时间明显短于高LncRNA PRAL表达组(P<0.05)。结论MM患者血清中LncRNA PRAL表达降低,血清中LncRNA PRAL低表达与高ISS分期及患者不良预后有关,有可能成为评估MM预后的重要指标。Objective To study the expression of long-chain non-coding RNA(LncRNA)PRAL in patients with multiple myeloma(MM)and its relationship with clinicopathological parameters and prognosis.Methods The clinical data of 82 patients with MM diagnosed and treated in the Second Affiliated Hospital of Nantong University(hereinafter referred to as“our hospital”)from January 2016 to January 2017 were selected as case group,50 patients with other blood diseases in the same period in our hospital were selected as case control group,and 51 persons with physical examination in the same period in our hospital were taken as healthy control group.Quantitative real-time PCR was used to detect the expression of serum LncRNA PRAL of each group,and the expression difference of each group and their relationship with clinicopathological characteristics were statistically analyzed.According to the mean value of serum LncRNA PRAL expression of 2.125,82 MM patients were divided into high LncRNA PRAL expression group(40 cases)and low LncRNA PRAL expression group(42 cases),the curative effect of the two groups was compared.The prognostic differences in patients with different LncRNA PRAL expression levels were analyzed by Kaplan-Meier survival analysis(Log-rank test).Results The expression of LncRNA PRAL in the case group was significantly lower than the case control group and the healthy control group(P<0.05).The expression of serum LncRNA PRAL of MM patients with high International staging system(ISS)stage was significantly lower than that in MM patients with low ISS stage(P<0.05),while the relative expression of serum LncRNA PRAL of patients with different age,gender,diagnostic typing,Durie-Salmon stage,blood lactate dehydrogenase,blood calcium and hemoglobin levels were not statistically significant(all P>0.05).The curative effect of patients with high expression of LncRNA PRAL was better than that of patients with low expression of LncRNA PRAL(P<0.05).The 3-year overall survival rate of low LncRNA PRAL expression group was significantl

关 键 词：多发骨髓瘤 LncRNA PRAL 临床病理特征 预后 

分 类 号：R733.1[医药卫生—肿瘤]